基本信息
views: 83
Career Trajectory
Bio
His team is developing new local ocular drug delivery systems including a new intraocular crystalline lipid prodrug delivery platform, a porous silicon based ocular drug delivery system, and transscleral drug delivery system. These drug delivery systems are an effective approach to achieve a sustained therapeutic drug level in the posterior segment of an eye. With these systems, patients can avoid frequent intravitreal injections for treatment of many refractory vitreoretinal diseases such as macular degeneration and diabetic macular edema. He and his colleague have been published extensively in the area of ocular drug delivery, ocular toxicology, ocular pharmacology, as well as clinical management of vitreoretinal diseases.
Research Interests
Papers共 99 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Scientific reportsno. 1 (2024): 13990-13990
Eyeno. 8 (2024): 1542-1548
Retinano. 3 (2024): 465-474
Retina (Philadelphia, Pa)no. 4 (2023): 555-559
Eyeno. 6 (2023): 1-7
Cited0Views0Bibtex
0
0
Jinlei Ma, Fangyuan Wu, Zhiyong Liu, Yijiong Fang, Xu Chu,Linyan Zheng,Anquan Xue,Kaihui Nan,Jia Qu,Lingyun Cheng
FRONTIERS IN MEDICINE (2022)
Cited0Views0Bibtex
0
0
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 101
#Citation: 2930
H-Index: 26
G-Index: 51
Sociability: 6
Diversity: 3
Activity: 17
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn